ALPINE GROUP PARTNERS, LLC. lobbying for EMERGENT BIOSOLUTIONS

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 19, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 2

HANNAH SCHMIDT

Previously held: Professional Staff, House Small Business Cmte
ERIN MENDELSOHN New on this filing

Previously held: LD, Rep. Anna Eshoo; Congressional Liaison - FDA

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Lobbying activity 2

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; Tribal Opioid Response Grant funding for FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025

Aviation/Airlines/Airports

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; Tribal Opioid Response Grant funding for FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025